FRAX597 - CAS 1286739-19-2
Catalog number: 1286739-19-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H28ClN7OS
Molecular Weight:
558.10
COA:
Inquire
Targets:
p21-activated Kinases (PAKs)
Description:
FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
N/A
MSDS:
Inquire
1.FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Yeo D1, He H2, Patel O3, Lowy AM4, Baldwin GS5, Nikfarjam M6. BMC Cancer. 2016 Jan 16;16:24. doi: 10.1186/s12885-016-2057-z.
BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer.
2.FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S1, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL. J Biol Chem. 2013 Oct 4;288(40):29105-14. doi: 10.1074/jbc.M113.510933. Epub 2013 Aug 19.
The p21-activated kinases (PAKs) are immediate downstream effectors of the Rac/Cdc42 small G-proteins and implicated in promoting tumorigenesis in various types of cancer including breast and lung carcinomas. Recent studies have established a requirement for the PAKs in the pathogenesis of Neurofibromatosis type 2 (NF2), a dominantly inherited cancer disorder caused by mutations at the NF2 gene locus. Merlin, the protein product of the NF2 gene, has been shown to negatively regulate signaling through the PAKs and the tumor suppressive functions of Merlin are mediated, at least in part, through inhibition of the PAKs. Knockdown of PAK1 and PAK2 expression, through RNAi-based approaches, impairs the proliferation of NF2-null schwannoma cells in culture and inhibits their ability to form tumors in vivo. These data implicate the PAKs as potential therapeutic targets. High-throughput screening of a library of small molecules combined with a structure-activity relationship approach resulted in the identification of FRAX597, a small-molecule pyridopyrimidinone, as a potent inhibitor of the group I PAKs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related p21-activated Kinases (PAKs) Products


FRAX486
(CAS: 1232030-35-1)

FRAX486, an effective PAK inhibitor, could improve epileptic seizures and sorts of other abnormal behaviors.

G‑5555
(CAS: 1648863-93-7)

G‑5555, a pyridopyrimidine derivative, has been found to be a PAK1 inhibitor that could be significant in anticancer studies. Ki=3.7 nM.

NVS PAK1 C

NVS PAK1 C is the negative control of NVS PAK1 1. NVS PAK1 1 is a potent and selective PAK1 inhibitor (IC50 = 5 nM). Selective for PAK1 over PAK2 and a panel of...

CAS 1286739-19-2 FRAX597

FRAX597
(CAS: 1286739-19-2)

FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

CAS 898044-15-0 PF-03758309

PF-03758309
(CAS: 898044-15-0)

PF-3758309, also known as PF-03758309, is a PAK4 inhibitor, is also an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potent...

PAK4-IN-1
(CAS: 1643913-93-2)

PAK4-IN-1, a substituted benzofuranyl compound, is an inhibitor of p21-activated kinases (PAKs). in MTT assay: IC50 ≤100 nM

FRAX1036
(CAS: 1432908-05-8)

FRAX1036 is a highly selective PAK1 inhibitor that remarkably altered signaling to cytoskeletal-associated proteins. In vitro and in vivo tests with FRAX-1036 h...

CAS 42521-82-4 IPA-3

IPA-3
(CAS: 42521-82-4)

IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).

G-5555 hydrochloride

G-5555 hydrochloride is the hydrochloride salt of G-5555 which is a potent and selective p21-activated kinase 1 (PAK1) inhibitor (Ki= 3.7 nM). G-5555 was potent...

CAS 2016806-57-6 AZ13705339

AZ13705339
(CAS: 2016806-57-6)

AZ13705339 is a potent and selective PAK1 inhibitor (IC50 = 0.33 nM). PAK1 is commonly overexpressed in breast tumors.

PF 3758309 dihydrochloride

PF 3758309 dihydrochloride is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 (IC50 = 1.3 nM; Kd = 2.7 nM). PF 3758309 inhibits phosphorylation of ...

CAS 6088-51-3 PIR 3.5

PIR 3.5
(CAS: 6088-51-3)

PIR 3.5 is a negative control of IPA 3, an allosteric inhibitor of group I PAK activation.

G-5555
(CAS: 1648863-90-4)

G-5555 is a selective PAK1 Inhibitor (Ki=3.7 nM) with low clearance (CLp = 3.4 mL/min/kg) and high oral bioavailability (F = 72%). IC50: PAK2= 11 nM, SIK2= 9 mM...

Chemical Structure

CAS 1286739-19-2 FRAX597

Quick Inquiry

Verification code

Featured Items